4

PRIMARY DOCUMENT

Company: REGENERON PHARMACEUTICALS, INC.
Filed: October 17, 2023
Period of Report: October 13, 2023
Accession Number: 0001968202-23-000037

View Document ↗ View on SEC.gov ↗